{"id":"762e6b13-a4ec-4fe6-9e2c-2aa4fb360d8e","authors":[{"author":{"id":"05f90f8f-95ec-427b-b09f-8d1a922c0852","openalex_id":"pmc:author:abalhassan_ia","orcid":null,"display_name":"Abalhassan IA","works_count":1,"cited_by_count":0,"h_index":0,"last_institution":null,"country_code":null},"position":"middle"},{"author":{"id":"28dd473e-ca68-43a1-b52f-d62225ceeb30","openalex_id":"pmc:author:alhussaini_ki","orcid":null,"display_name":"AlHussaini KI","works_count":8,"cited_by_count":0,"h_index":0,"last_institution":null,"country_code":null},"position":"first"},{"author":{"id":"4b7789d2-929d-4632-90e3-a7d8bac43b5b","openalex_id":"pmc:author:alhussaini_ai","orcid":null,"display_name":"Alhussaini AI","works_count":1,"cited_by_count":0,"h_index":0,"last_institution":null,"country_code":null},"position":"last"},{"author":{"id":"ef535262-0b93-4207-8363-80268a2c0ce4","openalex_id":"pmc:author:toraih_e","orcid":null,"display_name":"Toraih E","works_count":1,"cited_by_count":0,"h_index":0,"last_institution":null,"country_code":null},"position":"middle"}],"concepts":[],"publisher_name":null,"publisher_website_url":null,"publisher_info":null,"bib_extra":[],"journal_info":{"id":"20c79543-fd66-4a26-a841-0dabfaa2ca8f","slug":"pharmaceutics-19994923","sjr_quartile":"Q1","sjr_score":1.197,"sjr_year":2025,"sjr_history":{"2024":{"score":1.075,"quartile":"Q1","categories":["Pharmaceutical Science (Q1)"]},"2025":{"score":1.197,"quartile":"Q1","categories":["Pharmaceutical Science (Q1)"]}},"jif":5.5,"jif_quartile":"Q1","jif_year":2025,"doaj_seal":false,"is_curated":false,"ulke":"CH","url":"http://www.mdpi.com/journal/pharmaceutics/","h_index":178},"raw_data":{"abstract_tr":"Arka Plan: Propofol, kolorektal kanser cerrahisinde anestezi için yaygın olarak kullanılmaktadır, ancak sıklıkla hipotansiyon ve solunum depresyonu ile ilişkilidir. Remimazolam, benzeri anestezik derinlik ve iyileşme özellikleri ile birlikte daha iyi hemodinamik stabilite sunabilecek yeni bir ultra-kısa etkili benzodiazepindir. Ancak, kolon kanseri bağlamında remimazolam ve propofolü doğrudan karşılaştıran kanıtlar sınırlıdır.","title_en":"Remimazolam Versus Propofol for General Anesthesia in Older Adults Undergoing Colon Cancer Surgery: A Systematic Review and Meta-Analysis of Comparative Studies.","abstract_source":"crossref"},"openalex_id":"pmc:13118759","doi":"10.3390/pharmaceutics18040448","title":"Remimazolam Versus Propofol for General Anesthesia in Older Adults Undergoing Colon Cancer Surgery: A Systematic Review and Meta-Analysis of Comparative Studies.","publication_year":2026,"type":"article","cited_by_count":0,"is_open_access":true,"pdf_url":null,"abstract":"Background: Propofol is widely used for anesthesia in colorectal cancer surgery, but is frequently associated with hypotension and respiratory depression. Remimazolam, a novel ultra-short–acting benzodiazepine, may offer improved hemodynamic stability with similar anesthetic depth and recovery characteristics. However, evidence directly comparing remimazolam and propofol in the setting of colon cancer surgery remains limited. Therefore, the aim of this study was to systematically evaluate the efficacy, safety, perioperative hemodynamic stability, and recovery outcomes of remimazolam versus propofol in older adults undergoing colon cancer surgery. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials and comparative cohort studies evaluating remimazolam versus propofol in adult patients undergoing colon or colorectal cancer surgery. PubMed, Scopus, and Web of Science were searched from the start of each database to October 2025. Outcomes included perioperative hemodynamics (MAP and HR), recovery parameters, intraoperative remifentanil consumption, anesthesia duration, and adverse events. Random-effect models were used to calculate pooled mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs). Results: Six studies involving 542 patients (remimazolam n = 276; propofol n = 266) were included. Remimazolam produced significantly higher perioperative MAP (overall MD = 2.86 mmHg, 95% CI 1.52–4.21; p < 0.0001) and slightly higher HR (MD = 2.30 bpm, 0.08–4.52; p = 0.04). Differences were largest immediately after incision and at the end of surgery. No significant differences were found in PACU stay, overall recovery duration, remifentanil consumption, or anesthesia duration. Postoperative nausea and vomiting were comparable (RR = 0.93; p = 0.86), while respiratory depression was numerically lower with remimazolam (RR = 0.49; p = 0.17). Conclusions: Remimazolam provides anesthetic efficacy comparable to propofol in colon cancer surgery while offering modest, but clinically meaningful improvements in intraoperative hemodynamic stability. Recovery times, opioid requirements, and adverse-event rates were similar between agents. Remimazolam may be particularly advantageous for elderly or hemodynamically vulnerable patients undergoing major colorectal procedures. Larger, high-quality trials are warranted to clarify long-term and oncologic outcomes.","source_name":"Pharmaceutics","source_issn":null,"volume":null,"issue":null,"first_page":null,"last_page":null,"language":"en","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13118759/","is_relevant":true,"thesis_level":null,"title_tr":"Kolon kanseri ameliyatı geçiren yaşlı yetişkinlerde genel anestezi için remimazolam ve propofol karşılaştırmalı: karşılaştırmalı çalışmaların sistematik bir incelemesi ve meta-analizi.","license_code":"CC-BY","license_url":null,"doi_status":"unknown","doi_last_checked":null,"merged_at":null,"lens_id":"056-494-918-014-84X","patent_cited_by_count":null,"oa_colour":"Gold","created_at":"2026-05-05T04:30:45.914367+03:00","updated_at":"2026-06-03T13:10:14.901528+03:00","publisher":null,"merged_into":null}